Quick Answer
Design Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $16.86 million for the year ending 2025.
- Design Therapeutics, Inc. showed a decrease of -25.3% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Design Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 9, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2021: $400.69 million | Q2 2021: $370.84 million | Q3 2021: $357.66 million | Q1 2022: $287.31 million | Q2 2022: $119.65 million | Q3 2022: $42.52 million | Q1 2023: $28.81 million | Q2 2023: $27.20 million | Q3 2023: $27.94 million | Q1 2024: $29.40 million | Q2 2024: $45.70 million | Q3 2024: $30.33 million | Q1 2025: $13.67 million | Q2 2025: $19.70 million | Q3 2025: $15.09 million.
- Over the full 6 years of available data (2020 to 2025), Design Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 608.5%.
- Historical annual values: Fiscal year 2025: $16.86 million | Fiscal year 2024: $22.56 million | Fiscal year 2023: $21.20 million | Fiscal year 2022: $26.50 million | Fiscal year 2021: $298.57 million | Fiscal year 2020: $2.38 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: